Sanofi : Le T1 2024 passe sans encombre
>Un peu supérieur aux attentes - Sanofi publie ce matin ses résultats du T1 24 qui s’avèrent un peu au-dessus des attentes au niveau des ventes et de son BPA. Comme attendu Sanofi bénéficie d’un effet changes très négatif (-4.3% en topline et -10.2% en bottom line). Brièvement, les ventes totales du groupe ressortent à 10 464 M€ vs 10 272 M€e (+2.4% ; +6.7% à tcc), son core EBIT à 2 843 M€ vs 2 748 M€e (-14.7% ; -4.2% tcc) pour un Core BPA de 1.78 € vs 1.71 €e e...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.